Investigational Lassa Fever Vaccine Shows Promise in First-in-Human Phase 1 Trial

An investigational dual vaccine for Lassa fever and rabies has demonstrated significant immunogenicity and a favorable safety profile in a first-in-human Phase 1 clinical trial. The vaccine, vectored with inactivated rabies, showed a more than fourfold increase in antibodies against both Lassa virus glycoprotein complex and rabies glycoprotein in all participants who received two doses.